Moderna's Cancer Vaccine May Cut Deaths In Half | The Brainstorm 146

Personalized RNA cancer vaccines from Moderna and Merck mark a transition toward customized medicine, where patient-specific treatments target neoantigens to prime the immune system against aggressive cancers like melanoma. This shift toward bespoke therapy parallels the evolution of AI agents, specifically GrokBot, which demonstrate that agentic performance relies as much on "grit"—the ability to navigate complex, multi-step web tasks—as it does on raw intelligence. These autonomous agents are poised to disrupt enterprise workflows by acting as collaborative team members within communication channels, potentially unseating legacy software stacks. Meanwhile, immersive entertainment venues like COSM offer a social, high-fidelity alternative to the isolation of VR, successfully leveraging dynamic camera angles and wall-to-wall displays to create scalable, high-demand experiences that redefine traditional entertainment consumption.